JP2008511559A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008511559A5 JP2008511559A5 JP2007528648A JP2007528648A JP2008511559A5 JP 2008511559 A5 JP2008511559 A5 JP 2008511559A5 JP 2007528648 A JP2007528648 A JP 2007528648A JP 2007528648 A JP2007528648 A JP 2007528648A JP 2008511559 A5 JP2008511559 A5 JP 2008511559A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cell
- hiv
- agent
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 239000003795 chemical substances by application Substances 0.000 claims 14
- 210000004027 cell Anatomy 0.000 claims 10
- 210000001744 T-lymphocyte Anatomy 0.000 claims 8
- 230000000779 depleting effect Effects 0.000 claims 6
- 230000036436 anti-hiv Effects 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- 229960000548 alemtuzumab Drugs 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 210000000987 immune system Anatomy 0.000 claims 2
- 239000003607 modifier Substances 0.000 claims 2
- 229960003816 muromonab-cd3 Drugs 0.000 claims 2
- 102000013135 CD52 Antigen Human genes 0.000 claims 1
- 108010065524 CD52 Antigen Proteins 0.000 claims 1
- 108010044091 Globulins Proteins 0.000 claims 1
- 102000006395 Globulins Human genes 0.000 claims 1
- 101150003725 TK gene Proteins 0.000 claims 1
- 230000001494 anti-thymocyte effect Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000005728 strengthening Methods 0.000 claims 1
- 230000026683 transduction Effects 0.000 claims 1
- 238000010361 transduction Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60517304P | 2004-08-30 | 2004-08-30 | |
| PCT/EP2005/008325 WO2006024354A1 (en) | 2004-08-30 | 2005-07-28 | Treatment of hiv infection by t-cell modulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008511559A JP2008511559A (ja) | 2008-04-17 |
| JP2008511559A5 true JP2008511559A5 (https=) | 2008-09-11 |
Family
ID=35079284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007528648A Pending JP2008511559A (ja) | 2004-08-30 | 2005-07-28 | Ｔ−細胞を調節することによるｈｉｖ感染の治療 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20060057620A1 (https=) |
| EP (1) | EP1784217A1 (https=) |
| JP (1) | JP2008511559A (https=) |
| KR (1) | KR20070050934A (https=) |
| AU (1) | AU2005279460A1 (https=) |
| BR (1) | BRPI0514729A (https=) |
| CA (1) | CA2570735A1 (https=) |
| IL (1) | IL179856A (https=) |
| MX (1) | MX2007002188A (https=) |
| NO (1) | NO20071700L (https=) |
| RU (1) | RU2393872C2 (https=) |
| TW (1) | TW200626172A (https=) |
| WO (1) | WO2006024354A1 (https=) |
| ZA (1) | ZA200702654B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| JP2024520444A (ja) | 2021-05-24 | 2024-05-24 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を治療するための方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993008829A1 (en) * | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| US5795572A (en) * | 1993-05-25 | 1998-08-18 | Bristol-Myers Squibb Company | Monoclonal antibodies and FV specific for CD2 antigen |
| AU2265701A (en) * | 1999-12-16 | 2001-06-25 | Tanox, Inc. | Anti-hiv-1 conjugates for treatment of hiv disease |
| US20040147428A1 (en) * | 2002-11-15 | 2004-07-29 | Pluenneke John D. | Methods of treatment using an inhibitor of epidermal growth factor receptor |
-
2005
- 2005-07-28 JP JP2007528648A patent/JP2008511559A/ja active Pending
- 2005-07-28 MX MX2007002188A patent/MX2007002188A/es unknown
- 2005-07-28 WO PCT/EP2005/008325 patent/WO2006024354A1/en not_active Ceased
- 2005-07-28 CA CA002570735A patent/CA2570735A1/en not_active Abandoned
- 2005-07-28 KR KR1020077004665A patent/KR20070050934A/ko not_active Withdrawn
- 2005-07-28 BR BRPI0514729-8A patent/BRPI0514729A/pt not_active IP Right Cessation
- 2005-07-28 AU AU2005279460A patent/AU2005279460A1/en not_active Abandoned
- 2005-07-28 EP EP05773955A patent/EP1784217A1/en not_active Ceased
- 2005-07-28 RU RU2007111566/14A patent/RU2393872C2/ru not_active IP Right Cessation
- 2005-08-08 TW TW094126857A patent/TW200626172A/zh unknown
- 2005-08-29 US US11/212,906 patent/US20060057620A1/en not_active Abandoned
-
2006
- 2006-12-05 IL IL179856A patent/IL179856A/en not_active IP Right Cessation
-
2007
- 2007-03-29 ZA ZA200702654A patent/ZA200702654B/xx unknown
- 2007-03-30 NO NO20071700A patent/NO20071700L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Castagna et al. | The appealing story of HIV entry inhibitors: from discovery of biological mechanisms to drug development | |
| JP2006515883A5 (https=) | ||
| JP2013522302A5 (https=) | ||
| Pianko et al. | High Efficacy of Treatment with Sofosbuvir+ GS-5816±Riavirin for 12 Weeks in Treatment Experienced Patients with Genotype 1 or 3 HCV Infection: 197 | |
| JP2017514911A5 (https=) | ||
| JP2016537380A5 (https=) | ||
| JP2020523384A5 (https=) | ||
| JP2015172060A5 (https=) | ||
| JP2021501800A5 (https=) | ||
| JP2008511559A5 (https=) | ||
| JP2017502058A5 (https=) | ||
| Kalpoe et al. | Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal–pancreas transplantation | |
| Gordon et al. | Sofosbuvir+ Simeprevir is Safe in Liver Transplant Recipients: 706 | |
| Fabrizi et al. | Antiviral therapy for HCV-associated cryoglobulinemic glomerulonephritis: case report and review of the literature | |
| JP2023551193A5 (https=) | ||
| Rockstroh | HCV cure for everyone or which challenges remain? | |
| Bronowicki et al. | RESPONSE-GUIDED THERAPY (RGT) WITH BOCEPREVIR (BOC)+ PEGINTERFERON ALFA-2B/RIBAVIRIN (P/R) FOR TREATMENT-NAïVE PATIENTS WITH HEPATITIS C VIRUS (HCV) GENOTYPE (G) 1 WAS SIMILAR TO A 48-WK FIXED-DURATION REGIMEN WITH BOC+ P/R IN SPRINT-2: LB-15 | |
| RU2393872C2 (ru) | Лечение вич инфекции посредством т-клеточной модуляции | |
| CN107617101B (zh) | 含唑来膦酸和白细胞介素2的药物组合及其应用 | |
| Bhat et al. | Therapeutic modalities in the management of COVID-19: a worldwide landscape | |
| CN105749246A (zh) | 治疗丙肝病毒感染的阿拉泊韦 | |
| Jefferys | Research toward a cure and immune-based and gene therapies | |
| Larrey et al. | Sustained Virological Response after 14-D Ay Treatment with Danoprevir and 48-Week Treatment with Pegylated Interferon-α2A (40 Kd) plus Ribavirin | |
| Boras et al. | DRUG-INDUCED ORAL ULCERATIONS: CASE REPORT | |
| RU2568894C1 (ru) | Способ профилактики нейтропении у больных хроническим гепатитом с, получающих комбинированную противовирусную терапию |